Medicamen Organics IPO Details Today : Medicamen Organics IPO Details Today is Open on 21 June 2024 and Close on 25 June 2024. Medicamen Organics IPO to Raise 3,100,000 shares (Approx ₹10.54 Cr) via IPO. The Fresh issue of 3,100,000 shares (Approx ₹10.54 Cr).
We are engaged in developing, manufacturing and distribution of broad range of pharmaceutical dosage including generic dosage in form of Tablets, Capsules, Oral Liquids, Ointments, Gel, Syrups, Suspension and Dry powders for government (including both state and central governments) and private institutions as contract manufacturer / third party manufacturer.
We market our product to private pharma companies in domestic as well as international markets through third party distributors or on loan license basis. We have a track record of operating B2B model which covers contract manufacturing model.
Our products are marketed across India as well as African, CIS and south East Asian Countries like Congo, Benin, Cameg, Togo, Senegal, Burkina Faso, Philippines, Myanmar, Mozambique, Togo, Burundi, Kyrgyzstan and Kenya by our third-party distributor. we have entered into contract manufacturing with 38 domestic partners and 12 merchant exporters.
OUR PRODUCT PORTFOLIO
1. Capsules: – Various capsule formulation/compositions are being manufactured by us including but not limited to the following:-
- Rabeprazole and Domperidone to treat with Hyperacidity.
- Tacrolimus Capsule belongs to a class of drugs known as immunosuppressants.
- Ribavirin capsules is an antiviral medicine that is used in the treatment of chronic hepatitis C virus (HCV) infection. It prevents the multiplication of virus in human cells and clears up the infection.
2. Ointment/External Preparation: – We are producing antifungal/anti-bacterial formulations like Miconazole, Nystatin, Clotrimazole, Nadifloxacin, Mometasone in single as well as a composition form like cream and Gel. Topical Diclofenac, Salicylic acid composition are also being manufactured.
3. Suspension: – A variety of cough syrups, Multivitamin/Minerals, Calcium supplements, Antacid liquids, Iron supplements, Laxative liquids, Anthelmetic suspensions, anti-pyritic and anti-inflammatory suspensions are our key products.
4. Dry Powder Sachet:- We are manufacturing sachets like pre and probiotic in granular form. Diclofenac Potassium and Sodium granules for oral administration.
5. Tablet: – (also known as a pill): We are producing various composition of Ferrous and Folic Acid tablets. These tablets are widely used as an iron supplement to treat or prevent low blood levels of iron (such as those caused by anemia or pregnancy). Iron being an important mineral that the body needs to produce red blood cells keeps, an individual in good health. The formulation is developed in a manner to fulfil the deficiency quickly.
Medicamen Organics IPO Date & Price Band Details
| IPO Open Date | 21 June 2024 |
|---|---|
| IPO Close Date | 25 June 2024 |
| IPO Size | 3,100,000 shares (Approx ₹10.54 Cr) |
| Fresh Issue | 3,100,000 shares (Approx ₹10.54 Cr) |
| Lot Size | 4000 Shares |
| IPO Face Value | ₹10 Per Equity Share" |
| IPO Price Band | ₹32 to ₹34 Per Every Share |
| IPO Listing On | NSE SME |
| IPO Retail Quota | 35% |
| IPO QIB Quota | 50% |
| IPO NII Quota | 15% |
| DRHP Draft | Click Here |
| Anchor Investor | Click Here |
Medicamen Organics IPO Market Lot Details
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 4000 | ₹136,000 |
| Retail Maximum | 1 | 4000 | ₹136,000 |
| S-HNI Minimum | 2 | 8000 | ₹272,000 |
Object of the Issue
- Funding of expenses proposed to be incurred towards Product registration in the international markets.
- Plant updation and increase in production capacity.
- Funding working capital requirements of our Company.
- General Corporate Purposes.
Medicamen Organics IPO Allotment & Listings (Details)
| IPO Open Date | 21 June 2024 |
|---|---|
| IPO Close Date | 25 June 2024 |
| Basis of Allotment | 26 June 2024 |
| Refunds | 27 June 2024 |
| Credit to Demat Account | 27 June 2024 |
| IPO Listing Date | 28 June 2024 |
Medicamen Organics Financial Reports
| ₹ in Crores | |||
|---|---|---|---|
| Year | Revenue | Expense | PAT |
| Sept 2023 | ₹11.33 | ₹9.57 | ₹1.29 |
| 2023 | ₹22.96 | ₹21.60 | ₹0.96 |
| 2022 | ₹21.19 | ₹20.93 | ₹0.09 |
| 2021 | ₹25.06 | ₹24.57 | ₹0.30 |
Our Company Promoters
- Bal Kishan Gupta
Qualitative Factors
- Experienced Promoters and Management Team.
- Long standing relationships with customers.
- Efficient operational team.
- Consistent financial performance.
Medicamen Organics Comparison Listed Industry Peers Group
| Company Name | Face Value | EPS | P/E Ratio | Ro NW (%) | NAV Per | Revenue (₹ in Lakhs) |
|---|---|---|---|---|---|---|
| Medicamen Organics Limited | 10.00 | 1.60 | [.] | 11.25 | 14.20 | 2,296.24 |
| Peer Group | ||||||
| Brooks Laboratories Ltd | 10.00 | 12.57 | 10.60 | -28.26 | 30.10 | 6,340.80 |
| Cian Healthcare Ltd | 10.00 | 043 | 53.84 | 1.75 | 22.40 | 6,809.94 |
| Zenotech Laboratories Ltd | 10.00 | 1.90 | 38.76 | 14.08 | 14.20 | 4350.80 |
Comparison with listed industry peer
- Medicamen Organics Limited.
- Brooks Laboratories Ltd.
- Cian Healthcare Ltd.
- Zenotech Laboratories Ltd.
Medicamen Organics Company Contact Details
10 Community Centre No 2
Ashok Vihar Phase II,
New Delhi, Delhi, 110052, India.
Telephone: +91-9818222845
E-mail: cs@mediorganics.in
Investor grievance id: support@mediorganics.in
Website: www.medicamenorganics.com
Medicamen Organics IPO Registrar
KFIN TECHNOLOGIES LIMITED
Selenium Tower- B, Plot 31-32, Gachibowli, Financial District, Nanakramguda, Serilingampally,
Hyderabad-500 032, Telangana, India.
Tel No.: +91 40 6716 2222
Website: www.kfintech.com
Email: nvl.ipo@kfintech.com;
Investor Grievance Email: einward.ris@kfintech.com
Contact Person: Mr. M Murali Krishna
1 thought on “Medicamen Organics IPO details IPO Date, Price, GMP, Review, Details”